PTGX:NSD-Protagonist Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 47.02

Change

0.00 (0.00)%

Market Cap

USD 0.42B

Volume

0.62M

Analyst Target

USD 30.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing PTGX

FYC First Trust Small Cap Gro.. 0.78 % 0.70 %

+0.26 (+0.76%)

USD 0.32B
ETHO Amplify ETF Trust 0.55 % 0.45 %

+0.27 (+0.76%)

USD 0.18B
FYX First Trust Small Cap Cor.. 0.40 % 0.63 %

+0.74 (+0.76%)

USD 0.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 105.06% 91% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.06% 91% A- 95% A
Trailing 12 Months  
Capital Gain 162.68% 93% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.68% 93% A 97% N/A
Trailing 5 Years  
Capital Gain 226.07% 90% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 226.07% 90% A- 92% A
Average Annual (5 Year Horizon)  
Capital Gain 66.84% 87% B+ 92% A
Dividend Return 66.84% 87% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.93% 31% F 17% F
Risk Adjusted Return 63.10% 97% N/A 85% B
Market Capitalization 0.42B 91% A- 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.29 33% 52%
Price/Book Ratio 5.12 25% 22%
Price / Cash Flow Ratio -39.43 97% 94%
Price/Free Cash Flow Ratio 14.25 5% 24%
Management Effectiveness  
Return on Equity 40.69% 99% 96%
Return on Invested Capital 78.72% 92% 97%
Return on Assets 20.35% 100% 99%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.